BZE2204 / Shanghai Cell Therapy Group - LARVOL DELTA

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Myositis • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura • CXCL8 • IL13 • IL4

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd | Active, not recruiting ➔ Recruiting | Trial completion date: Jul 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CXCL8 • IL15 • IL4

JL-lightning CAR-T, a next generation non-viral CAR-T without in-vitro culturing procedure, shows high clinical efficacy, good safety with low treatment dosage (AACR 2025) - "In vitro experiments showed both versions of BZE2204 exerted strong cytotoxicity on CD19-, CD22- and BCMA-positive tumor cells with high CAR-T cell expansion rates, superior stemness and low exhaustion phenotype compared with conventional CAR-T. V-6h, which has the shortest process, displayed the highest T-stem and proliferation among all groups. In vivo models showed V-30h BZE2204 inhibited tumor growth and significantly prolonged mice lifespan under super low dosage (1E5 CAR-T/mouse)."

Preclinical • Hematological Malignancies • Lymphoma • Oncology • CD22

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology